{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:28:49Z","timestamp":1773293329712,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s11914-996-0025-2","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T12:54:18Z","timestamp":1180702458000},"page":"159-164","source":"Crossref","is-referenced-by-count":36,"title":["Treatment of children with osteogenesis imperfecta"],"prefix":"10.1007","volume":"4","author":[{"given":"Frank","family":"Rauch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis H.","family":"Glorieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"25_CR1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH: Osteogenesis imperfecta. Lancet 2004, 363:1377\u20131385.","journal-title":"Lancet"},{"key":"25_CR2","unstructured":"Morello R, Bertin T, Chen Y, et al.: CRTAP is required for collagen 3-prolyl-hydroxylation and loss of its function causes recessive osteogenesis imperfecta. Cell, In press."},{"key":"25_CR3","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0003-9993(98)90426-9","volume":"79","author":"RH Engelbert","year":"1998","unstructured":"Engelbert RH, Pruijs HE, Beemer FA, Helders PJ: Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil 1998, 79:1590\u20131594.","journal-title":"Arch Phys Med Rehabil"},{"key":"25_CR4","first-page":"77","volume":"12","author":"L Zeitlin","year":"2003","unstructured":"Zeitlin L, Fassier F, Glorieux FH: Modern approach to children with osteogenesis imperfecta. J Pediatr Orthop B 2003, 12:77\u201387.","journal-title":"J Pediatr Orthop B"},{"key":"25_CR5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0003-9993(98)90207-6","volume":"79","author":"LH Gerber","year":"1998","unstructured":"Gerber LH, Binder H, Berry R, et al.: Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Arch Phys Med Rehabil 1998, 79:46\u201351.","journal-title":"Arch Phys Med Rehabil"},{"key":"25_CR6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","volume":"339","author":"FH Glorieux","year":"1998","unstructured":"Glorieux FH, Bishop NJ, Plotkin H, et al.: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998, 339:947\u2013952.","journal-title":"N Engl J Med"},{"key":"25_CR7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, et al.: Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005, 20:977\u2013986.","journal-title":"J Bone Miner Res"},{"key":"25_CR8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","volume":"39","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Munns CF, et al.: Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006, 39:901\u2013906.","journal-title":"Bone"},{"key":"25_CR9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH: The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002, 110:1293\u20131299.","journal-title":"J Clin Invest"},{"key":"25_CR10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","volume":"20","author":"CF Munns","year":"2005","unstructured":"Munns CF, Rauch F, Travers R, Glorieux FH: Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005, 20:1235\u20131243.","journal-title":"J Bone Miner Res"},{"key":"25_CR11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jpeds.2005.10.041","volume":"148","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Montpetit K, et al.: Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006, 148:456\u2013460.","journal-title":"J Pediatr"},{"key":"25_CR12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, et al.: Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005, 20:758\u2013763.This is the first controlled, randomized study on intravenous bisphosphonate treatment in children with osteogenesis imperfecta. Sixty-four children were randomized to receive either neridronate or placebo. The neridronate group sustained fewer fractures in the first treatment year.","journal-title":"J Bone Miner Res"},{"key":"25_CR13","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","volume":"359","author":"PD Delmas","year":"2002","unstructured":"Delmas PD: Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018\u20132026.","journal-title":"Lancet"},{"key":"25_CR14","first-page":"S12","volume":"19","author":"FH Glorieux","year":"2004","unstructured":"Glorieux FH, Rauch F, Ward LM, et al.: Alendronate in the treatment of pediatric osteogenesis imperfecta. J Bone Miner Res 2004, 19:S12.","journal-title":"J Bone Miner Res"},{"key":"25_CR15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, et al.: Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004, 363:1427\u20131431.In this placebo-controlled, double-blind, randomized study, treatment with oral olpadronate was associated with a lower incidence of long-bone fractures.","journal-title":"Lancet"},{"key":"25_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","volume":"21","author":"LA Meglio Di","year":"2006","unstructured":"DiMeglio LA, Peacock M: Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006, 21:132\u2013140.","journal-title":"J Bone Miner Res"},{"key":"25_CR17","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1210\/jc.2004-2054","volume":"90","author":"LM Ward","year":"2005","unstructured":"Ward LM, Denker AE, Porras A, et al.: Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005, 90:4051\u20134056.","journal-title":"J Clin Endocrinol Metab"},{"key":"25_CR18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00247-003-0865-1","volume":"33","author":"LE Grissom","year":"2003","unstructured":"Grissom LE, Harcke HT: Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003, 33:226\u2013229.","journal-title":"Pediatr Radiol"},{"key":"25_CR19","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","volume":"19","author":"F Rauch","year":"2004","unstructured":"Rauch F, Travers R, Munns C, Glorieux FH: Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004, 19:1191\u20131193.","journal-title":"J Bone Miner Res"},{"key":"25_CR20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","volume":"86","author":"E Astrom","year":"2002","unstructured":"Astrom E, Soderhall S: Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002, 86:356\u2013364.","journal-title":"Arch Dis Child"},{"issue":"5","key":"25_CR21","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","volume":"111","author":"L Zeitlin","year":"2003","unstructured":"Zeitlin L, Rauch F, Plotkin H, Glorieux FH: Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003, 111(5Pt 1):1030\u20131036.","journal-title":"Pediatrics"},{"key":"25_CR22","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","volume":"12","author":"SA Khan","year":"1997","unstructured":"Khan SA, Kanis JA, Vasikaran S, et al.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700\u20131707.","journal-title":"J Bone Miner Res"},{"key":"25_CR23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Ward L, Glorieux FH: Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004, 19:1742\u20131745.","journal-title":"J Bone Miner Res"},{"key":"25_CR24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1359\/JBMR.051207","volume":"21","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Glorieux FH: Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006, 21:374\u2013379.","journal-title":"J Bone Miner Res"},{"key":"25_CR25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, et al.: Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004, 19:1779\u20131786.This study showed that treatment with intravenous pamidronate was a significant risk factor for delayed healing of osteotomy sites after intramedullary rodding procedures. However, there was no detectable effect of pamidronate therapy on fracture healing.","journal-title":"J Bone Miner Res"},{"key":"25_CR26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","volume":"7","author":"CA Migliorati","year":"2006","unstructured":"Migliorati CA, Siegel MA, Elting LS: Bisphosphonateassociated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006, 7:508\u2013514.","journal-title":"Lancet Oncol"},{"key":"25_CR27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1440-1754.2003.00083.x","volume":"39","author":"JA Batch","year":"2003","unstructured":"Batch JA, Couper JJ, Rodda C, et al.: Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 2003, 39:88\u201392.","journal-title":"J Paediatr Child Health"},{"key":"25_CR28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2004.07.003","volume":"35","author":"LA Meglio Di","year":"2004","unstructured":"DiMeglio LA, Ford L, McClintock C, Peacock M: Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004, 35:1038\u20131045.","journal-title":"Bone"},{"key":"25_CR29","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1359\/jbmr.2003.18.4.610","volume":"18","author":"F Rauch","year":"2003","unstructured":"Rauch F, Plotkin H, Zeitlin L, Glorieux FH: Bone mass, size and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003, 18:610\u2013614.","journal-title":"J Bone Miner Res"},{"key":"25_CR30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2005-2036","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Travers R, Glorieux FH: Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006, 91:511\u2013516.","journal-title":"J Clin Endocrinol Metab"},{"key":"25_CR31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Munns C, Land C, Glorieux FH: Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006, 91:1268\u20131274.","journal-title":"J Clin Endocrinol Metab"},{"key":"25_CR32","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1055\/s-0028-1093710","volume":"7","author":"HP Kruse","year":"1975","unstructured":"Kruse HP, Kuhlencordt F: On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975, 7:488\u2013491.","journal-title":"Horm Metab Res"},{"key":"25_CR33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","volume":"129","author":"F Antoniazzi","year":"1996","unstructured":"Antoniazzi F, Bertoldo F, Mottes M, et al.: Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 1996, 129:432\u2013439.","journal-title":"J Pediatr"},{"key":"25_CR34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S8756-3282(99)00186-6","volume":"25","author":"NE Vieira","year":"1999","unstructured":"Vieira NE, Marini JC, Hopkins E, et al.: Effect of growth hormone treatment on calcium kinetics in patients with osteogenesis imperfecta type III and IV. Bone 1999, 25:501\u2013505.","journal-title":"Bone"},{"key":"25_CR35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","volume":"18","author":"JC Marini","year":"2003","unstructured":"Marini JC, Hopkins E, Glorieux FH, et al.: Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003, 18:237\u2013243.","journal-title":"J Bone Miner Res"},{"key":"25_CR36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","volume":"26","author":"F Rauch","year":"2000","unstructured":"Rauch F, Travers R, Parfitt AM, Glorieux FH: Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 2000, 26:581\u2013589.","journal-title":"Bone"},{"key":"25_CR37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, et al.: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002, 30:312\u2013321.","journal-title":"Toxicol Pathol"},{"key":"25_CR38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/sj.gt.3302199","volume":"11","author":"C Niyibizi","year":"2004","unstructured":"Niyibizi C, Wang S, Mi Z, Robbins PD: Gene therapy approaches for osteogenesis imperfecta. Gene Ther 2004, 11:408\u2013416.","journal-title":"Gene Ther"},{"key":"25_CR39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molmed.2005.04.006","volume":"11","author":"S Millington-Ward","year":"2005","unstructured":"Millington-Ward S, McMahon HP, Farrar GJ: Emerging therapeutic approaches for osteogenesis imperfecta. Trends Mol Med 2005, 11:299\u2013305.","journal-title":"Trends Mol Med"},{"key":"25_CR40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ymthe.2005.02.015","volume":"12","author":"BE Peace","year":"2005","unstructured":"Peace BE, Florer JB, Witte D, et al.: Endogenously expressed multimeric self-cleaving hammerhead ribozymes ablate mutant collagen in cellulo. Mol Ther 2005, 12:128\u2013136.","journal-title":"Mol Ther"},{"key":"25_CR41","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.ejhg.5201230","volume":"12","author":"S Millington-Ward","year":"2004","unstructured":"Millington-Ward S, McMahon HP, Allen D, et al.: RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 2004, 12:864\u2013866.","journal-title":"Eur J Hum Genet"},{"key":"25_CR42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.1088757","volume":"303","author":"JR Chamberlain","year":"2004","unstructured":"Chamberlain JR, Schwarze U, Wang PR, et al.: Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 2004, 303:1198\u20131201.","journal-title":"Science"},{"key":"25_CR43","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","volume":"95","author":"RF Pereira","year":"1998","unstructured":"Pereira RF, O\u2019Hara MD, Laptev AV, et al.: Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A 1998, 95:1142\u20131147.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"25_CR44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","volume":"5","author":"EM Horwitz","year":"1999","unstructured":"Horwitz EM, Prockop DJ, Fitzpatrick LA, et al.: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309\u2013313.","journal-title":"Nat Med"},{"key":"25_CR45","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","volume":"97","author":"EM Horwitz","year":"2001","unstructured":"Horwitz EM, Prockop DJ, Gordon PL, et al.: Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97:1227\u20131231.","journal-title":"Blood"},{"key":"25_CR46","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"99","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM, Gordon PL, Koo WK, et al.: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932\u20138937.","journal-title":"Proc Natl Acad Sci USA"},{"key":"25_CR47","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","volume":"79","author":"Blanc K Le","year":"2005","unstructured":"Le Blanc K, Gotherstrom C, Ringden O, et al.: Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79:1607\u20131614.","journal-title":"Transplantation"},{"key":"25_CR48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bone.2003.11.019","volume":"34","author":"P Arikoski","year":"2004","unstructured":"Arikoski P, Silverwood B, Tillmann V, Bishop NJ: Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy x-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004, 34:539\u2013546.","journal-title":"Bone"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-996-0025-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-996-0025-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:33:58Z","timestamp":1559421238000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-996-0025-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s11914-996-0025-2","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}